Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Gastrointestinal Neoplasms 1Clonal Cytopenia of Undetermined Significance 1Carcinoma, Renal Cell 1

Interventions

Fluorouracil 9Oxaliplatin 7Leucovorin 7Surveys and Questionnaires 6Blood Specimen Collection 6Bevacizumab 6Specimen Handling 5Gemcitabine 5Cetuximab 5Capecitabine 5fludarabine 4aldesleukin 4Standard of Care 4Irinotecan 4Cyclophosphamide 4Remote Patient Monitoring 3Radiosurgery 3Pafolacianine 3Nivolumab 3Endoscopic Mucosal Resection 3Cisplatin 3130-nm albumin-bound paclitaxel 3encorafenib 2Tomography, X-Ray Computed 2Sunitinib 2Referral and Consultation 2Radiotherapy 2Practice Guidelines as Topic 2Pemetrexed 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × canakinumab × 1 year × Clear all
NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

Phase 1 Active not recruiting
9 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡